Piramal Pharma Ltd (Mumbai)

Piramal Pharma Ltd maintains a capital structure characterized by significant leverage, with long-term debt of INR 56.7 billion against total equity of INR 81.6 billion, resulting in a debt-to-equity ratio of 0.7. The company holds INR 2.25 billion in cash and equivalents, which is insufficient to cover its total debt, leading to a negative net cash position. Liquidity is assessed as medium, supported by a current ratio of 1.51, indicating adequate short-term assets to meet immediate liabilities. Operating cash flow stands at INR 16.5 billion, providing a buffer against the negative free cash flow of INR 4.1 billion, which is driven by substantial capital expenditures of INR 8.9 billion.

Profitability metrics indicate financial distress in the current period, with a net loss of INR 3.26 billion and an operating income of only INR 420.6 million against revenue of INR 88.7 billion. Return on equity is negative at -3.99%, and return on assets is -1.81%, reflecting the inability of the current asset base to generate positive returns. The gross profit of INR 53.7 billion suggests a gross margin of approximately 60.5%, but operating expenses and other costs erode this margin significantly, leading to the net loss. Without cohort median data for direct comparison, the negative returns stand out as a critical deviation from typical industry profitability norms.

Revenue concentration and segment details are not explicitly provided in the available data, preventing a detailed analysis of geographic or product-specific exposure. The company's total revenue of INR 88.7 billion serves as the aggregate base for all financial metrics. In the absence of segment breakdowns, the analysis relies on the consolidated financial performance, which shows a high gross profit but low net income, suggesting high operating leverage or significant non-operating charges.

Growth trajectory analysis is limited by the absence of historical period data in the input. The current financial snapshot shows a single period's performance, with no year-over-year or quarter-over-quarter trends available to assess momentum. The significant capital expenditure of INR 8.9 billion relative to the negative free cash flow suggests ongoing investment in capacity or R&D, but the impact on future revenue growth cannot be quantified from the provided data.

Risk assessment highlights medium liquidity risk and low dilution risk. The key flag of negative net cash after subtracting total debt underscores the refinancing risk associated with the INR 56.7 billion long-term debt. The low dilution risk is supported by the identical basic and diluted share counts of 1.33 billion, indicating no significant outstanding options or convertible securities that would dilute equity in the near term.

Recent investor relations observations show strong analyst sentiment, with a mean recommendation of 1.40 (strong buy) and a mean price target of INR 206.30. There are 6 strong buy and 4 buy ratings, with no hold ratings, suggesting confidence in the company's future prospects despite current profitability challenges. The price target range spans from INR 175.00 to INR 255.00, indicating a potential upside from current levels if the company addresses its net loss and debt burden.

There are no material changes to report for Piramal Pharma Ltd (PIRM.NS) based on the available data. The analysis of 17 fields, excluding four schema-expansion fields, indicates no significant shifts compared to prior assessments. The company's profile remains static with one officer and no analyst coverage. Additionally, there is no index membership or top holder data available to suggest changes in market positioning or ownership structure. Cross-source signals show minimal activity, with only one dispatch recorded on July 6, 2026, and zero dispatches on all other days within the 30-day window from June 25 to July 15, 2026. Sentiment data is not available for these periods. Given the absence of material changes, watcher signals, or significant news dispatches, there is no new information to impact the company's outlook. Investors should continue to monitor for future updates, as the current data reflects a period of stability without notable developments.